NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Nuvig Therapeutics

Nuvig Therapeutics

Private
Menlo Park, CaliforniaHealthcare & Life Scienceshttps://nuvigtx.com/

Last Round

Series B

Dec 5, 2024

Total Funding Raised

$208M

Company Overview

Nuvig Therapeutics is a biotechnology company that develops innovative immunomodulatory therapies to restore immune homeostasis and treat chronic inflammatory and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyimmunomodulatorchronic inflammatory demyelinating polyneuropathyCIDPclinical trialsbiologicsautoimmune diseasebiotech startupprotein engineeringdrug developmentclinical-stage biotechtherapeutic assetsbiopharmalicensing agreementventure-backed biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nuvig Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Nuvig Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Nuvig Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BDec 5, 2024
Series AMay 11, 2022

Key People

Founding team and executive leadership

David Woodhouse

Chief Executive Officer

Executive Team

Nuvig Therapeutics Investors

Notable investors and investment history

Nuvig Therapeutics investors
InvestorRounds
Aberdeen Group plcSeries B
Digitalis VenturesSeries A, Series B
RM Global PartnersSeries B
abrdn Inc.Series B
B Capital GroupSeries B
TD SecuritiesSeries B
Blue Owl CapitalSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 18, 2025

    Celia J.F. Lin, M.D. appointed as Chief Medical Officer.

  • Sep 9, 2025

    James Mackay appointed as Independent Board Chair.

Nuvig Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Nuvig Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Nuvig Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersMenlo Park, California
Employee Range24
Year Founded2021
Last FundingDec 5, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.